POXEL Employee Directory
Biotechnology ResearchAuvergne-rhône-alpes, France11-50 Employees
POXEL is a clinical-stage biotechnology company focused on therapies for chronic metabolic diseases, including non-alcoholic steatohepatitis and rare inherited disorders. Its pipeline combines AMPK activation and deuterated TZD approaches to address metabolic dysfunction, with programs spanning NASH and inherited metabolic conditions. In NASH, PXL065 is in a streamlined Phase 2 trial, and PXL770 has completed a Phase 2a proof-of-concept study; the company also plans Phase 2a proof-of-concept work in adrenomyeloneuropathy using these assets, while its TWYMEEG (Imeglimin) targets mitochondrial dysfunction and has been approved and launched in Japan for type 2 diabetes. POXEL is headquartered in Lyon, France, and maintains subsidiaries in Boston and Tokyo, while being listed on Euronext Paris. The company has a strategic partnership with Sumitomo Dainippon Pharma to advance Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian markets.
1-888-653-2347 
support@leadiq.com 
